Sensei Biotherapeutics Inc Total Liabilities
Sensei Biotherapeutics Inc total liabilities. Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has total liabilities worth $14.19 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SNSE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sensei Biotherapeutics Inc (2018–2025)
Total liabilities of Sensei Biotherapeutics Inc from 2018 to 2025. This chart illustrates how Sensei Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Sensei Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Panca Global Securities Tbk
JK:PEGE
|
Indonesia | Rp46.19 Billion |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
USA | $7.63 Million |
|
Studio Mir Co. Ltd.
KQ:408900
|
Korea | ₩3.93 Billion |
|
Namibia Critical Metals Inc
V:NMI
|
Canada | CA$1.33 Million |
|
Muar Ban Lee Group Bhd
KLSE:5152
|
Malaysia | RM103.00 Million |
|
Drillcon AB
ST:DRIL
|
Sweden | Skr266.49 Million |
|
Dongkuk Refractories & Steel Co. Ltd
KQ:075970
|
Korea | ₩45.90 Billion |
|
Dignitana AB
ST:DIGN
|
Sweden | Skr24.80 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Sensei Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sensei Biotherapeutics Inc total assets.
Liquidity & Leverage Metrics
Sensei Biotherapeutics Inc Total Liabilities Ratios Explained
Sensei Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sensei Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Sensei Biotherapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.31 Million | -38.21% |
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more